Scinai Immunotherapeutics (SCNI) Current Deferred Revenue (2015 - 2025)
Scinai Immunotherapeutics' (SCNI) quarterly Current Deferred Revenue came in at $90000.0 in Q4 2025, down 60.0% year-over-year from $225000.0 in Q4 2024, and down 60.0% quarter-over-quarter from $225000.0 in Q4 2024.
Powered by 
Analysis
Scinai Immunotherapeutics (SCNI) Current Deferred Revenue (2015 - 2025) Analysis & Trends
Scinai Immunotherapeutics has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $90000.0 for Q4 2025.
- In Q4 2025, Current Deferred Revenue fell 60.0% year-over-year to $90000.0; the TTM figure through Dec 2025 stood at $90000.0 (down 60.0% YoY), while the FY2025 annual figure was $90000.0, down 60.0% from the prior year.
- Current Deferred Revenue came in at $90000.0 for Q4 2025 at Scinai Immunotherapeutics, down from $225000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $225000.0 in Q4 2024 to a low of $90000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Scinai Immunotherapeutics | 1.52 Bn | 1.52 Bn | -1.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 90,000.00 |
| Dec 31, 2024 | 225,000.00 |
| Jun 30, 2015 | 2.11 Mn |